Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

Summary

This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).

Timeline

Start

2026-10

Primary completion

2028-10

Completion

2032-10

Drugs

Indications